Latest MDS Research To Be Presented At The 52nd Meeting Of The American Society Of Hematology (ASH 2010)
Published: Dec 1, 2010 10:53 am
The 52nd annual meeting of the American Society of Hematology kicks off this Saturday, December 4, in Orlando.
During the four-day meeting, clinical specialists from all over the world will discuss current research regarding the diagnosis and treatment of various blood diseases, including myelodysplastic syndromes (MDS). Over 20,000 people are expected to attend the event.
The American Society of Hematology (ASH) meeting will include many presentations and talks focused on MDS. The ASH website currently lists over 150 MDS-based abstracts that will be presented in various poster sessions and oral presentations throughout the conference.
The MDS Beacon will be covering the event, so readers can expect many articles in the upcoming weeks about the key MDS findings from the meeting.
An MDS education program is scheduled for both Saturday and Sunday. Dr. Guillermo Garcia-Manero from the MD Anderson Cancer Center in Houston will be talking about the prognosis of patients with MDS. Dr. Corey Cutler from the Dana-Farber Cancer Institute in Boston will discuss the role of stem cell transplantation in MDS, and Dr. William Blum from The Ohio State University Comprehensive Cancer Center will present a clinical guide to new therapies in MDS.
On Sunday, several presentations about molecular mechanisms in MDS will be given. In addition, Dr. Azra Raza, an MDS expert at St. Vincent’s Comprehensive Cancer Center in New York, will speak about general MDS topics.
Morning sessions on Monday, will deal with molecular profiling as a diagnostic and prognostic tool in MDS as well as prognosis and response to treatment.
During the afternoon session on Monday, researchers will share clinical trial results for current and new drugs for the treatment of MDS, such anti-thymocyte globulin (ATG) and Vidaza (azacitidine) in combination with Zolinza (vorinostat).
During Tuesday’s MDS session, experts will discuss MDS-related diagnostic and therapeutic markers.
Over 130 posters specific to MDS research will be displayed in three separate poster sessions at the ASH meeting.
Posters on Saturday will highlight several potential new treatments for MDS, including Tarceva (erlotinib), Nplate (romiplostim), and combination therapies with Vidaza. Posters on Sunday will cover a variety of topics, including Revlimid (lenalidomide), iron overload, and chromosomal abnormalities. Posters on Monday will include additional research on Vidaza, stem cell transplantation, and potential new prognostic tools.
Additional information about the ASH meeting, including details about registration, the meeting schedule, and abstracts, can be found at the ASH website.
- Latest MDS Research To Be Presented At The 51st Meeting Of The American Society Of Hematology (ASH 2009)
- Latest MDS Research Findings To Be Presented At The American Society Of Hematology Annual Meeting (ASH 2011)
- MDS Beacon To Report Latest MDS Research From Upcoming American Society Of Hematology Annual Meeting (ASH 2012)
- Latest MDS Research To Be Presented At The American Society Of Clinical Oncology’s 2010 Annual Meeting (ASCO 2010)
- Myelodysplastic Syndromes Treatments Discussed At ASCO’s 45th Annual Meeting (ASCO 2009)